<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03700034</url>
  </required_header>
  <id_info>
    <org_study_id>CTRI/2019/01/016857</org_study_id>
    <nct_id>NCT03700034</nct_id>
  </id_info>
  <brief_title>mHealth Integrated Model of Hypertension, Diabetes and Antenatal Care in India and Nepal</brief_title>
  <official_title>A Cluster-randomized Trial of an mHealth Integrated Model of Hypertension, Diabetes and Antenatal Care in Primary Care Settings in India and Nepal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Public Health Foundation of India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kathmandu University School of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Public Health Foundation of India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial aims to enhance antenatal care (ANC) to address the changing disease burden
      affecting pregnant women in India and Nepal. The enhancement includes using a tablet-based
      electronic decision support system that prompts front line health workers to provide
      evidence-based routine ANC, enhances detection and management of pregnancy-induced
      hypertension and gestational diabetes, facilitates record-keeping and reporting, and links
      across levels of care providers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators propose to develop and evaluate the use of mHealth to enhance antenatal
      care (ANC) in primary care settings of India and Nepal. Currently, the usual pathways for
      obtaining ANC in India and Nepal start with Accredited Social Health Activists (ASHAs) and
      Female Community Health Volunteers (FCHVs) respectively. These workers mobilize pregnant
      women in the community to attend ANC services with Auxiliary Nurse Midwifes (ANMs), who
      provide routine ANC, and refer women to physicians (MBBS doctors) at PHCs, or higher levels
      of care, as required. However, health programme managers and providers in both India and
      Nepal are cognizant of concerns over current ANC practice, and wish to enhance ANC in a
      number of ways. First, they recognize the changing disease burden and rising importance of
      PIH and GDM, and seek to increase access to specialized care when needed.

      The investigators propose using an EDSS intervention to enhance ANC. EDSS can allow FHWs to
      incorporate screening, detection and referral of high-risk pregnancies for appropriate
      clinical management into routine ANC services to improve glucose and blood pressure control
      and health outcomes for both mothers and babies. EDSS should also improve adherence to
      National ANC guidelines and provide an integrated continuum of maternal care services across
      several levels of care.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of pregnant women receiving at least four antenatal check-ups</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women who receive at least 4 ANC check-ups between the two arms (mHealth integrated ANC and routine ANC). A pregnant woman is supposed to make at least four visits throughout her pregnancy, distributed according to her period of gestation as follows:
1st visit, within 12 weeks; preferably as soon as pregnancy is suspected for registration of pregnancy and first antenatal check-up
2nd visit: Between 14 and 26 weeks
3rd visit: Between 28 and 34 weeks
4th visit: Between 36 weeks and term It should be emphasised that this is only a minimum requirement and that more visits may be necessary, depending on the woman's condition and needs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of pregnant women getting their blood pressure measured</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women whose blood pressure was measured on all ANC visits between the two arms (mHealth integrated ANC and routine ANC). According to the &quot;Guidelines for antenatal care and skilled attendance at birth (2010)&quot; by the Government of India, blood pressure has to be measured on every visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of pregnant women receiving urine test for proteinuria</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women tested for proteinuria between the two arms (mHealth integrated ANC and routine ANC). This test is used for the detection of pre-eclampsia, which (along with eclampsia) is one of the five major causes of maternal mortality According to the &quot;Guidelines for antenatal care and skilled attendance at birth (2010)&quot; by the Government of India, a woman should be tested for proteinuria on every visit or at least the 4 prescribed ANC visits (1st visit, within 12 weeks; 2nd visit, between 14 and 26 weeks; 3rd visit, between 28 and 34 weeks; 4th visit, between 36 weeks and term).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of pregnant women receiving blood glucose test</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women tested for blood glucose between the two arms (mHealth integrated ANC and routine ANC). This is a test used to diagnose women with gestational diabetes.
According to the &quot;Guidelines for antenatal care and skilled attendance at birth (2010)&quot; by the Government of India, a woman should be tested for urine sugar on every visit or at least all the 4 prescribed ANC visits (1st visit, within 12 weeks; 2nd visit, between 14 and 26 weeks; 3rd visit, between 28 and 34 weeks; 4th visit, between 36 weeks and term).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of pregnant women receiving haemoglobin test</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women tested for haemoglobin between the two arms (mHealth integrated ANC and routine ANC). This is performed with a hemoglobinometer and is used to diagnose women with anemia. According to the &quot;Guidelines for antenatal care and skilled attendance at birth (2010)&quot; by the Government of India, a woman's haemoglobin estimation should be performed on every visit or at least all the 4 prescribed ANC visits (1st visit, within 12 weeks; 2nd visit, between 14 and 26 weeks; 3rd visit, between 28 and 34 weeks; 4th visit, between 36 weeks and term).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of pregnant women tetanus toxoid protection</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women who received two doses of tetanus toxoid injections between the two arms (mHealth integrated ANC and routine ANC).
According to the &quot;Guidelines for antenatal care and skilled attendance at birth (2010)&quot; by the Government of India, the first dose of TT should be administered as soon as possible, preferably when the woman registers for ANC. The second dose is to be given one month after the first, preferably at least one month before the Expected Date of Delivery (EDD).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of pregnant women receiving counselling</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of pregnant women counselled between the two arms (mHealth integrated ANC and routine ANC).
According to the &quot;Guidelines for antenatal care and skilled attendance at birth (2010)&quot; by the Government of India, the following components should be covered under counselling: birth preparedness (including identification of a facility for delivery, complication readiness, diet and rest, breastfeeding, sex during pregnancy, domestic violence and, family planning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of pregnant women identified with Gestational Diabetes Mellitus</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of women identified with Gestational Diabetes Mellitus (GDM) between the two arms (mHealth integrated ANC and routine ANC).
To identify women with GDM, the universal single step screening criteria recommended by the International Association of Diabetes and Pregnancy Study Groups (IADPSG) in 2010 and later adapted by World Health Organization (WHO) and the American Diabetes Association (ADA) in 2013 and 2015, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of pregnant women identified with Pregnancy Induced Hypertension</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of women identified with Pregnancy Induced Hypertension (PIH) between the two arms (mHealth integrated ANC and routine ANC).
Pregnancy Induced Hypertension will be defined as blood pressure greater than 140/90 mmHg after 20 weeks in previously normotensive women (Hypertensive Disorders of Pregnancy ISSHP Classification from Brown et al 2018)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of pregnant women with Gestational Diabetes Mellitus (GDM) whose blood glucose was controlled to recommended targets</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of women whose blood glucose levels were controlled to recommended targets: Pre-meal â‰¤ 95 mg/dl (fasting); goals (mg/dL):1-hour &lt;140 and 2-hour &lt;120 (Postprandial glucose)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women with Pregnancy Induced Hypertension (PIH) whose blood pressure was controlled to recommended targets</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>Difference in proportion of women whose blood pressure levels were controlled to recommended targets i.e., less than 140/90 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of women with adverse pregnancy and neonatal outcomes</measure>
    <time_frame>One month post-delivery</time_frame>
    <description>'Adverse pregnancy and neonatal outcome' in this study will imply the presence of at least one or more of the following conditions in the current pregnancy as noted from the case records of these women: fetal malpresentation, miscarriage, unplanned caesarean delivery, pregnancy-related hypertensive disorders, gestational diabetes mellitus (GDM), intrauterine growth restriction (IUGR), major obstetric haemorrhage, preterm labor birth (PTB)/preterm delivery (PTD), low birth weight (&lt;2500 g), macrosomia (&gt;4000 g), neonatal congenital anomalies, neonatal respiratory distress syndrome (RDS), neonatal resuscitation (NR) or neonatal intensive care unit (NICU) admission, periventricular leucomalacia (PVL), stillbrith, neonatal death, postpartum hemorrhage (PPH), maternal intensive care unit (ICU) admission; Grade 3 and 4 intraventicular hemorrhage (IVH), retinopathy of prematurity (ROP).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1760</enrollment>
  <condition>Gestational Diabetes Mellitus (GDM)</condition>
  <condition>Pregnancy Induced Hypertension (PIH)</condition>
  <condition>Anemia</condition>
  <arm_group>
    <arm_group_label>mHealth Integrated Antenatal Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The mIRA trial intervention will consist of an electronic decision support system (EDSS), provided to healthcare providers at primary-level facilities in India and Nepal to deliver enhanced ANC with improved detection and management of pregnancy-induced hypertension (PIH), gestational diabetes mellitus (GDM) and anemia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Antenatal Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>In the control clusters, pregnant women will receive the existing standard of care (usual care) from Frontline Health Workers (FHWs).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mHealth Integrated Model of Antenatal Care</intervention_name>
    <description>Non-physician front line health workers (FHWs) will screen, detect, and refer PIH and GDM cases. Physicians will be trained to manage PIH and GDM. In the intervention clusters, pregnant women will receive enhanced antenatal care via a Frontline Health Worker (FHW), supported by an electronic decision support system (EDSS). This will integrate the screening, detection, and referral/management of GDM and PIH with existing antenatal care services, prompt FHWs to provide routine care, and help them record and report data upwards. Non-physician FHWs will not prescribe treatments, but they will carry out all other duties including diagnosis, referral to an appropriate physician to prescribe drugs, provide lifestyle advice, follow-up, and subsequently support adherence to management plans.</description>
    <arm_group_label>mHealth Integrated Antenatal Care</arm_group_label>
    <other_name>Electronic Decision Based System (EDSS)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant women in first trimester attending the ANC at the selected PHCs or associated
             sub-centres/health posts/sub-health posts

          -  Pregnant women who are willing to provide written informed consent

        Exclusion Criteria:

          -  Pregnant women currently participating in another related clinical trial

          -  Pregnant women planning to move residence in the year ahead.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dorairaj Prabhakaran, DM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vice President, Research and Policy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sailesh Mohan, PhD</last_name>
    <phone>9650335597</phone>
    <email>smohan@phfi.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Primary Health Centres (PHCs)</name>
      <address>
        <city>Asifabad</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Health Centres (PHCs)</name>
      <address>
        <city>Medak</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Health Centres (PHCs)</name>
      <address>
        <city>Rangareddy</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Health Centres</name>
      <address>
        <city>Siddipet</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Kalpana Basany, MD</last_name>
      <phone>9849569712</phone>
      <email>kalpanabasany@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Primary Health Centres (PHCs)</name>
      <address>
        <city>Vikarabad</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primary Health Centres (PHCs)</name>
      <address>
        <city>Yadadri Bhuvnagiri</city>
        <state>Telangana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health posts</name>
      <address>
        <city>Dhulikhel</city>
        <country>Nepal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>Nepal</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 4, 2018</study_first_submitted>
  <study_first_submitted_qc>October 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2018</study_first_posted>
  <last_update_submitted>January 23, 2020</last_update_submitted>
  <last_update_submitted_qc>January 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Public Health Foundation of India</investigator_affiliation>
    <investigator_full_name>Dorairaj Prabhakaran</investigator_full_name>
    <investigator_title>Vice President - Research and Policy</investigator_title>
  </responsible_party>
  <keyword>Antenatal care</keyword>
  <keyword>Pregnancy care</keyword>
  <keyword>Pregnancy complications</keyword>
  <keyword>Pregnancy Induced Hypertension</keyword>
  <keyword>Gestational Diabetes Mellitus</keyword>
  <keyword>Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

